Canada’s health regulator has authorized the COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX). Pfizer submitted documentation related to the BNT162b2 vaccine to Canadian regulators on Oct. 9, 2020. “Canadians can feel confident that the review process was rigorous and that we have strong monitoring systems in place,” Health Canada explained in a statement. The agency also stressed…
Trump’s latest drug pricing plan will likely face legal challenges
President Trump recently unveiled his latest initiative to standardize drug pricing, tying government drug payments to lower prices abroad. Trump also signaled his intent to eliminate pharmaceutical industry middlemen — pharmacy-benefit managers — who are “ripping off Medicare patients with high prescription prices,” he said. The policies, the president claimed, are the “the biggest ever…
5 takeaways from the latest White House Coronavirus Task Force meeting
The White House Coronavirus Task Force promised a swift rollout of COVID-19 vaccines — but one of a number of takeaways from its first briefing since July. The briefing yesterday gave the task force a chance to once again urge Americans to heed COVID-19 guidance while also providing an update on vaccines and therapeutics. The…
Indivior Solutions ordered to pay $289 million in Suboxone case
A federal judge in Virginia has sentenced opioid-addiction drug maker Indivior Solutions (LON:INDV) to pay $289 million in criminal penalties linked to the marketing of the drug Suboxone, the U.S. Department of Justice announced. In all, Indivior will pay a total of $600 million to resolve civil and criminal liabilities for downplaying safety risks tied…
What a Biden administration could mean for the pharma industry
While President Trump continues to refuse to concede the election, a growing number of business associations and politicians have acknowledged Biden as the president-elect. What a Biden presidency would mean for the pharmaceutical industry continues to be an open question as the Senate outcome remains undecided, but two broadly similar outcomes are likely. Ultimately, neither…
Boehringer to settle thousands of cases that allege Pradaxa bleeding risk
Boehringer Ingelheim has reached an agreement in principle to settle some 2,935 lawsuits tied to its blood thinner Pradaxa (dabigatran etexilate). In a Connecticut Supreme Court filing, privately owned Boehringer (Ingelheim am Rhein, Germany) stated the settlement would resolve the lawsuits, which alleged the anticoagulant drug Pradaxa caused undisclosed bleeding risks. The company expects it will…
Study: Hydroxychloroquine not warranted for hospitalized COVID-19 patients
A National Institutes of Health clinical trial has concluded that hydroxychloroquine had no clinical benefit for hospitalized COVID-19 patients. The Journal of the American Medical Association published the results from the blinded, placebo-controlled, randomized trial. The clinical trial, known as the “ORCHID” study, treated 479 symptomatic COVID-19 patients with hydroxychloroquine in 34 hospitals in the…
Nostrum Laboratories recalls Type 2 diabetes drug over contamination problems
Nostrum Laboratories is initiating the voluntary recall of two lots of its Metformin HCI extended-release tablets for people with diabetes. According to an FDA news release, the Metformin HCI extended-release tablets (USP 750mg) were found to contain levels of nitrosamine impurities above the ADI limit of 96ng per day, as stipulated in the FDA Guidance Document…
5 ways Election Day could impact pharma
The pharmaceutical industry stands at a crossroads as Election Day nears in the U.S. The election could ultimately have sweeping implications for the sector, or it could yield only modest changes. While the presidential election could have a significant influence on the pharma sector, arguably more important is who gains control of Congress. A blue sweep…
J&J exec denies pressure to rush COVID-19 vaccine
Johnson & Johnson’s (NYSE:JNJ) chief scientific officer said today that the first doses of his company’s COVID-19 vaccine could be available for frontline healthcare workers in January or February, but added the company isn’t rushing it. If granted an emergency use authorization by the FDA, that’s the earliest Dr. Paul Stoffels said the single-dose vaccine developed…